Kymera Therapeutics (KYMR) closed at $136.64 on November 10, 2026, down 1.6% from the previous close, on volume of 966,612 shares (30-day average 929,017).
Data as of November 10, 2026.
10-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 9, 2026 | Ratio Call Spread 1 by 1.5 | 18-Dec-26135 : 185[1.5x] C | 1,300 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 10, 2026. See the 10 largest for 30, 60 and 90 days
Cathie Wood's Ark Invest buys $96M of SpaceX, adds to Nvidia and AMD; trims Broadcom
Seeking Alpha News (Mon, 9-Nov 7:05 AM ET)
Globe Newswire (Thu, 29-Oct 7:00 AM ET)
Kymera Therapeutics to Announce KT-579 Phase 1 Healthy Volunteer Trial Results on October 29, 2026
Globe Newswire (Wed, 28-Oct 4:01 PM ET)
Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026
Globe Newswire (Thu, 22-Oct 4:01 PM ET)
PRNewswire (Mon, 12-Oct 9:31 AM ET)
Kuehn Law Encourages Investors of Kymera Therapeutics, Inc. to Contact Law Firm
PRNewswire (Wed, 30-Sep 8:59 AM ET)
Kymera Therapeutics to Participate in Upcoming September Investor Conferences
Globe Newswire (Wed, 2-Sep 4:01 PM ET)
Globe Newswire (Tue, 1-Sep 7:00 AM ET)
Market Chameleon (Thu, 25-Jun 5:19 AM ET)
Kymera Extends Cash Runway to 2029 as STAT6 and IRF5 Programs Advance Through Key Milestones
Market Chameleon (Thu, 26-Feb 3:06 AM ET)
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.
Kymera Therapeutics trades on the NASDAQ stock market under the symbol KYMR.
As of November 10, 2026, KYMR stock price declined to $136.64 with 966,612 million shares trading.
KYMR has a beta of 0.64, meaning it tends to be less sensitive to market movements. KYMR has a correlation of 0.02 to the broad based SPY ETF.
KYMR has a market cap of $11.67 billion. This is considered a Large Cap stock.
Last quarter Kymera Therapeutics reported $0 in Revenue and -$1.32 earnings per share. This fell short of revenue expectation by $-4 million and missed earnings estimates by -$.05.
In the last 3 years, KYMR traded as high as $142.92 and as low as $13.96.
The top ETF exchange traded funds that KYMR belongs to (by Net Assets): VTI, IWM, VB, XBI, VBK.
KYMR has outperformed the market in the last year with a price return of +123.0% while the SPY ETF gained +11.2%. KYMR has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +25.8% and +16.2%, respectively, while the SPY returned -2.7% and -2.6%, respectively.
KYMR support price is $134.00 and resistance is $143.72 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KYMR shares will trade within this expected range on the day.
